NIH TRND program: successes in preclinical therapeutic development.
作者信息
McKew John C, Pilon Andre M
机构信息
Therapeutics for Rare and Neglected Diseases (TRND) Program, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
出版信息
Trends Pharmacol Sci. 2013 Feb;34(2):87-9. doi: 10.1016/j.tips.2012.10.001. Epub 2012 Nov 19.
Abstract
摘要
相似文献
1
NIH TRND program: successes in preclinical therapeutic development.
Trends Pharmacol Sci. 2013 Feb;34(2):87-9. doi: 10.1016/j.tips.2012.10.001. Epub 2012 Nov 19.
2
NIH program to boost pipeline for drugs to treat rare and neglected diseases.
JAMA. 2009 Jul 8;302(2):133-4. doi: 10.1001/jama.2009.940.
3
The role of academic institutions in the development of drugs for rare and neglected diseases.
Clin Pharmacol Ther. 2012 Aug;92(2):193-202. doi: 10.1038/clpt.2012.83. Epub 2012 Jul 4.
4
New models for pharmaceutical innovation in low-income countries.
Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658.
5
NIH program helps developers navigate path to new drugs for neglected diseases.
JAMA. 2012 Feb 8;307(6):549-50. doi: 10.1001/jama.2012.83.
6
Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.
Curr Top Med Chem. 2014;14(3):330-9. doi: 10.2174/1568026613666131127160118.
7
Big pharma moves from 'blockbusters' to 'niche busters'.
Nat Med. 2010 Aug;16(8):837. doi: 10.1038/nm0810-837a.
8
Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases.
Drug Discov Today. 2020 Feb;25(2):274-291. doi: 10.1016/j.drudis.2019.10.015. Epub 2019 Nov 5.
9
In silico repositioning of approved drugs for rare and neglected diseases.
Drug Discov Today. 2011 Apr;16(7-8):298-310. doi: 10.1016/j.drudis.2011.02.016. Epub 2011 Mar 1.
10
Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
Health Aff (Millwood). 2012 Nov;31(11):2528-35. doi: 10.1377/hlthaff.2012.0235.
引用本文的文献
1
New Financial and Research Models for Pediatric Orphan Drug Development - Focus on the NCATS TRND Program.
Pharmaceut Med. 2014 Feb 1;28(1):1-6. doi: 10.1007/s40290-014-0047-5.
2
Rare diseases research: expanding collaborative translational research opportunities.
Chest. 2013 Jul;144(1):16-23. doi: 10.1378/chest.13-0606.
本文引用的文献
1
Future directions of sickle cell disease research: the NIH perspective.
Pediatr Blood Cancer. 2012 Aug;59(2):353-7. doi: 10.1002/pbc.24180. Epub 2012 Apr 19.
2
The Valley of Death in anticancer drug development: a reassessment.
Trends Pharmacol Sci. 2012 Apr;33(4):173-80. doi: 10.1016/j.tips.2012.02.001. Epub 2012 Mar 10.
3
Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership.
Cancer Res. 2012 Mar 1;72(5):1055-8. doi: 10.1158/0008-5472.CAN-11-3439. Epub 2012 Jan 13.
4
Reengineering translational science: the time is right.
Sci Transl Med. 2011 Jul 6;3(90):90cm17. doi: 10.1126/scitranslmed.3002747.
5
How to improve R&D productivity: the pharmaceutical industry's grand challenge.
Nat Rev Drug Discov. 2010 Mar;9(3):203-14. doi: 10.1038/nrd3078. Epub 2010 Feb 19.
6
Lessons from 60 years of pharmaceutical innovation.
Nat Rev Drug Discov. 2009 Dec;8(12):959-68. doi: 10.1038/nrd2961.
7
Sickle cell anemia, a molecular disease.
Science. 1949 Apr 29;109(2835):443.
Zotero 插件